NDA 022063 · Takeda Pharms USA
Mydayis
Amphetamine Aspartate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate · Oral
Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Jun 20, 2017
Approved uses
2
Original approval plus efficacy supplements
Registered trials
5
3 Phase 3, 0 recruiting
FAERS reports
879
184 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ABUSE, MISUSE, AND ADDICTION MYDAYIS ® has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including MYDAYIS, can result in overdose and death [see Overdosage (10) ] , and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing MYDAYIS, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout MYDAYIS treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions (5.1) , Drug Abuse and Dependence (9.2) ]. WARNING: ABUSE, MISUSE, AND ADDICTION...
What it is approved for
From the label in effect Apr 30, 2026.
MYDAYIS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older [see Clinical Studies (14) ] . MYDAYIS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 13 years and older. ( 1 ) Limitations of Use : Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose and experienced higher rates of adverse reactions, mainly insomnia and decreased appetite. ( 8.4 ) Limitations of Use : Pediatric patients 12 years and younger experienced higher plasma exposure than patients 13 years and older at the same dose, and experienced higher rates of adverse reactions, mainly insomnia and decreased appetite [see Use in Specific Populations (8.4) ] .
Mechanism: Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD is not known.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 13, 2019 Supplement 1 · Efficacy · priority review LetterLabel
- Jun 20, 2017 Original approval · Type 3 - New Dosage Form LabelLetterPediatric Medical Review
4 products under this application
- MYDAYIS · AMPHETAMINE ASPARTATE 9.375MG; AMPHETAMINE SULFATE 9.375MG; DEXTROAMPHETAMINE SACCHARATE 9.375MG; DEXTROAMPHETAMINE SULFATE 9.375MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2
- MYDAYIS · AMPHETAMINE ASPARTATE 3.125MG; AMPHETAMINE SULFATE 3.125MG; DEXTROAMPHETAMINE SACCHARATE 3.125MG; DEXTROAMPHETAMINE SULFATE 3.125MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2
- MYDAYIS · AMPHETAMINE ASPARTATE 12.5MG; AMPHETAMINE SULFATE 12.5MG; DEXTROAMPHETAMINE SACCHARATE 12.5MG; DEXTROAMPHETAMINE SULFATE 12.5MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2
- MYDAYIS · AMPHETAMINE ASPARTATE 6.25MG; AMPHETAMINE SULFATE 6.25MG; DEXTROAMPHETAMINE SACCHARATE 6.25MG; DEXTROAMPHETAMINE SULFATE 6.25MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2
Clinical trials
Interventional ClinicalTrials.gov studies with "Amphetamine Aspartate" as an intervention, any sponsor and status, largest first.
- Safety of SPD465 in Treating Adults With ADHD.Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00152035 · 505 participants · Start Mar 10, 2005 · Primary completion Nov 7, 2006
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. · For: Attention Deficit Disorder With Hyperactivity
- Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00152022 · 412 participants · Start Apr 25, 2005 · Primary completion Nov 4, 2005
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate. · For: Attention Deficit Disorder With Hyperactivity
- Efficacy and Safety of SPD465 in Adults With ADHDPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00150579 · 240 participants · Start Jan 27, 2005 · Primary completion Jun 14, 2005
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate · For: Attention Deficit Disorder With Hyperactivity
ShireTakeda (TAK)
NCT00202605 · 72 participants · Start Sep 29, 2005 · Primary completion Jan 6, 2006
Drug: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate · For: Attention Deficit Disorder With Hyperactivity
Sites: Little Rock, Arkansas; Irvine, California; Las Vegas, Nevada · 4 sites in all
ShireTakeda (TAK)
NCT03327402 · 24 participants · Start Mar 13, 2018 · Primary completion Oct 5, 2018
Drug: SHP465 · For: Attention Deficit Hyperactivity Disorder (ADHD)
Sites: Little Rock, Arkansas; Orlando, Florida; Evansville, Indiana · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective219
- fatigue61
- insomnia57
- headache53
- anxiety49
- off label use49
- feeling abnormal47
- product availability issue47
- no adverse event46
- inability to afford medication43
- somnolence41
- insurance issue39
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 83 |
| 2018 | 239 |
| 2019 | 97 |
| 2020 | 79 |
| 2021 | 95 |
| 2022 | 62 |
| 2023 | 81 |
| 2024 | 72 |
| 2025 | 40 |
| 2026 | 31 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mydayis (Dextroamphetamine/Amphetamine)
2024 spending
$1.3M
Beneficiaries
737
3,902 claims
Per beneficiary
$1,797
$11.00 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,529,481 |
| 2021 | $1,649,959 |
| 2022 | $1,826,993 |
| 2023 | $2,533,863 |
| 2024 | $1,324,735 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Eight-Week Randomized, Double-Blind, Placebo-Controlled 2-Site Trial Assessing the Efficacy and Safety of Mixed Amphetamine Salt as an Adjunctive Therapy for Bipolar Depression.
Frye MA, Sanchez-Ruiz JA, Nunez N, et al. · J Clin Psychiatry 2026 · Randomized Controlled Trial, Multicenter Study
- A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.
Mattingly G, Arnold V, Yan B, et al. · J Child Adolesc Psychopharmacol 2020 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.